The legal action, spearheaded by Hagens Berman, targets a period between January 14, 2025, and April 26, 2026. During this time, Erasca reportedly marketed ERAS-0015 as a superior pan-RAS molecular glue. The complaint asserts the company bolstered these claims through flawed preclinical comparisons against rival therapies and failed to disclose mounting patent infringement disputes with Revolution Medicines.
Market confidence collapsed on April 27, 2026, following the revelation of these undisclosed legal challenges and a patient death linked to clinical trials. The subsequent stock price decline erased more than $2.8 billion in market capitalization. Reed Kathrein, a partner at Hagens Berman, stated the firm is investigating whether the company intentionally obfuscated critical safety risks and competitive vulnerabilities to inflate its valuation. Investors holding losses from this period are encouraged to contact the firm, as are potential whistleblowers with non-public information.
Comments (0)
No comments yet. Be the first!